The rising trend of breast cancer both in developed and developing countries is a real threat challenging all efforts to screening, prevention and treatment aspects to reduce its impact. In spite of modern preventive strategies, the upward trend of breast cancer has become a matter of great concern in both developed and developing countries. Chittaranjan National Cancer Institute is a premier regional cancer institute in eastern region of India catering to a large number of cancer patients every year. A pilot case control study of fifty breast cancer patients and 100 matched controls was conducted during 2013 to evaluate the effects of habitual factors like working in night shift, not having adequate sleep, and not sleeping in total darkness on breast cancer of women. The study revealed that not sleeping in total darkness was associated with higher odds of outcome of breast cancer of women. This positive correlation can play a vital role in formulation of preventive strategies through life style modification.
Breast cancer is the most occurring malignancy among females worldwide. According to Globocan 2018 around 34.4 % of total cancer cases, breast cancer shows higher mortality rate of 11.3% with poor survival. Among all the subtypes of breast cancer, HER2+ cases have a lower survival rate with high recurrence in both Hispanic and Caucasian population. In tumor microenvironment (TME), immune cells play diverse roles either as antitumor or pro‐tumor effectors under specific cytokine stimulation. The negative immune check point markers like programmed cell death 1 (PD1), programmed cell death ligand 1 (PDL‐1) and their exhaustion markers play the crucial role in cancer prognosis by suppressing the immune system in cancer progression and metastasis. The higher expression of these immunoregulatory molecules predominantly shows the poor prognosis in breast cancer malignancies. In the current chemotherapy regime for HER2+ breast cancer cases, patient receives the monoclonal antibody, trastuzumab in combination with an anti‐microtubule agent docetaxel. Few recent studies showed that trastuzumab itself downregulates the PD1, PDL‐1 expression and also effects the functions of tumor infiltrating lymphocytes (TILs). But the synergetic role of these chemotherapeutics in regulating immune response and disease progression are yet to be studied. In this study, we have examined the effect of both docetaxel and trastuzumab on the negative immune checkpoint markers (PDL‐1, PD1, TIM3, LAG3 etc.) along with CD4+/CD8+ TILs using IHC and flowcytometry in HER2+ breast cancer patients, received neo‐ adjuvant chemotherapy (NACT) treatment before and adjuvant therapy after the surgery, cells isolated from tumor tissue and peripheral blood. Pre‐surgery NACT patients have a high infiltration of CD4+/CD8+ ratio in tumor as well as in peripheral blood than post‐surgery adjuvant treatment. Together with the increase of CD4+/CD8+ ratio, pre‐surgery NACT treated group has a comparatively lower expression of negative immune checkpoint markers and the exhaustion markers. Our finding is that the NACT received before surgery decreases the expression of negative immune checkpoint markers and the exhaustion markers together with the increase of CD4+/CD8+ ratio in HER2+ breast cancer as compared with the patients with adjuvant therapy after surgery. This study will emphasize on the combine effect of two chemotherapeutic arms in the treatment regime, before and after surgery of HER2+ breast cancer that could improve the survival rate.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.